EPAS1 and cancer: Given that we observed few, if any, effects of HIF2A on translation, our results suggest that the combined use of these HIF2A transcriptional inhibitors, together with mTOR inhibitors, should therefore be considered as a rational therapeutic strategy for this type of cancer.